Nature重磅：中国博后一作，发现全新免疫检查点，突破T细胞抗癌枷锁

Core Viewpoint - The article discusses the discovery of a new immune checkpoint, SLAMF6, which plays a crucial role in T cell-mediated anti-tumor immunity and presents a potential new target for cancer immunotherapy, complementing or even replacing existing PD-1/PD-L1 inhibitors [3][12][17]. Group 1: Limitations of Traditional Immunotherapy - Current PD-1/PD-L1 inhibitors work by blocking the interaction between PD-1 on T cells and PD-L1 on tumor cells, but not all tumors express PD-L1, and some patients develop resistance over time [6][5]. - There is a pressing need to identify new immune checkpoints to benefit a broader range of cancer patients [3]. Group 2: Disruptive Discovery of SLAMF6 - SLAMF6 is identified as a key suppressor of T cell immunity against cancer, functioning through a unique mechanism called "cis-interaction," where SLAMF6 molecules on the same T cell surface interact to exert a "self-inhibition" effect [3][11]. - Research shows that T cells lacking SLAMF6 exhibit stronger activation and anti-tumor effects, regardless of whether tumor cells express SLAMF6 [9][11]. Group 3: From Laboratory to Clinical Application - The research team developed monoclonal antibodies that effectively block human SLAMF6, significantly enhancing T cell activation and reducing exhausted T cell proportions in various mouse tumor models, outperforming PD-L1 inhibitors [13][15]. - The combination of SLAMF6 antibodies with PD-L1 inhibitors shows synergistic effects, suggesting new avenues for combination therapies [15]. Group 4: Safety and Future Prospects - No severe side effects, such as cytokine storms, were observed with SLAMF6 antibody treatment, providing a solid foundation for clinical development [17]. - Future steps include optimizing antibody design, potentially developing bispecific antibodies to target T cells in the tumor microenvironment more specifically [17].